Cinctive Capital Management LP Purchases Shares of 44,416 Liquidia Co. (NASDAQ:LQDA)

Cinctive Capital Management LP acquired a new position in shares of Liquidia Co. (NASDAQ:LQDA) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 44,416 shares of the company’s stock, valued at approximately $444,000. Cinctive Capital Management LP owned about 0.06% of Liquidia as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Quest Partners LLC acquired a new stake in Liquidia during the second quarter worth about $27,000. Deuterium Capital Management LLC acquired a new stake in Liquidia during the 2nd quarter worth approximately $120,000. Clear Harbor Asset Management LLC purchased a new position in Liquidia in the third quarter valued at approximately $100,000. Signaturefd LLC lifted its position in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares in the last quarter. Finally, DMC Group LLC purchased a new stake in Liquidia during the second quarter worth approximately $122,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Trading Up 0.3 %

LQDA stock opened at $11.26 on Wednesday. The company has a market capitalization of $953.05 million, a P/E ratio of -6.91 and a beta of 0.22. The firm has a 50 day simple moving average of $10.78 and a 200-day simple moving average of $11.33. Liquidia Co. has a twelve month low of $6.83 and a twelve month high of $16.99.

Insiders Place Their Bets

In related news, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Kaseta sold 3,892 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares in the company, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,007 shares of company stock valued at $245,780 in the last ninety days. Corporate insiders own 30.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LQDA shares. Bank of America cut their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Scotiabank began coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $24.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).